QM · rank #14 · 2026-07-23
SNT
GPW · PLN · $826M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +54.46% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $826M |
| Anchor (recent) Close on 2026-06-23 | $309.00 |
| Anchor (far) Close on 2025-06-23 | $200.05 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. distributes advanced medical devices, produces proprietary radiopharmaceuticals, and provides healthcare IT solutions to clinical centers across Central Europe.
Rationale
High TTM profitability and strong momentum are validated by a robust 163 million PLN order backlog, rising recurring revenues, and new European expansion pathways via the CE-certified Edison system.
Material risks
- 1Heavy reliance on third-party distribution rights for high-end systems like da Vinci robotic platforms makes the commercial moat vulnerable to changes in OEM partner strategies.
- 2Trailing quant metrics (55% ROE) are artificially inflated by a massive one-off 261.3 million PLN gain on the spin-off and listing of cardiotracer developer Syn2bio.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.